Tags

Type your tag names separated by a space and hit enter

Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.
Pharmacol Biochem Behav. 2010 Nov; 97(1):92-100.PB

Abstract

In view of its potential advantages, drug polytherapy is currently attracting significant interest in the field of obesity research. In this context, concurrent manipulation of serotonergic and cannabinoid pathways in rodents has been found to reduce food and fluid intake in both an additive or synergistic manner. To further assess the value of this polytherapeutic approach, the current study examined the acute effects of low-dose combinations of the cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (0.5 mg/kg) and the dual serotonin- and noradrenaline-reuptake inhibitor sibutramine (0.125 and 0.25 mg/kg) in male rats. Ethological analysis was used to generate comprehensive behavioural profiles, including the behavioural satiety sequence (BSS). Findings confirmed that, although neither drug given alone significantly altered food intake, feeding behaviour or weight gain, rimonabant per se tended to reduce consumption and time spent feeding while significantly increasing scratching and grooming responses. However, none of these effects of the CB1 receptor antagonist/inverse agonist was significantly altered by the presence of either dose of sibutramine. In striking contrast to recent reports of acute low-dose interactions (enhanced appetite suppression and reduced side-effects) between rimonabant and naloxone, present results would not appear to support the clinical potential of rimonabant/sibutramine polytherapy for obesity.

Authors+Show Affiliations

Institute of Psychological Sciences, University of Leeds, Leeds, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20026165

Citation

Tallett, A J., et al. "Effects of Acute Low-dose Combined Treatment With Rimonabant and Sibutramine On Appetite and Weight Gain in Rats." Pharmacology, Biochemistry, and Behavior, vol. 97, no. 1, 2010, pp. 92-100.
Tallett AJ, Blundell JE, Rodgers RJ. Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. Pharmacol Biochem Behav. 2010;97(1):92-100.
Tallett, A. J., Blundell, J. E., & Rodgers, R. J. (2010). Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. Pharmacology, Biochemistry, and Behavior, 97(1), 92-100. https://doi.org/10.1016/j.pbb.2009.12.010
Tallett AJ, Blundell JE, Rodgers RJ. Effects of Acute Low-dose Combined Treatment With Rimonabant and Sibutramine On Appetite and Weight Gain in Rats. Pharmacol Biochem Behav. 2010;97(1):92-100. PubMed PMID: 20026165.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats. AU - Tallett,A J, AU - Blundell,J E, AU - Rodgers,R J, Y1 - 2009/12/21/ PY - 2009/07/20/received PY - 2009/10/16/revised PY - 2009/12/14/accepted PY - 2009/12/23/entrez PY - 2009/12/23/pubmed PY - 2011/9/16/medline SP - 92 EP - 100 JF - Pharmacology, biochemistry, and behavior JO - Pharmacol Biochem Behav VL - 97 IS - 1 N2 - In view of its potential advantages, drug polytherapy is currently attracting significant interest in the field of obesity research. In this context, concurrent manipulation of serotonergic and cannabinoid pathways in rodents has been found to reduce food and fluid intake in both an additive or synergistic manner. To further assess the value of this polytherapeutic approach, the current study examined the acute effects of low-dose combinations of the cannabinoid CB1 receptor antagonist/inverse agonist rimonabant (0.5 mg/kg) and the dual serotonin- and noradrenaline-reuptake inhibitor sibutramine (0.125 and 0.25 mg/kg) in male rats. Ethological analysis was used to generate comprehensive behavioural profiles, including the behavioural satiety sequence (BSS). Findings confirmed that, although neither drug given alone significantly altered food intake, feeding behaviour or weight gain, rimonabant per se tended to reduce consumption and time spent feeding while significantly increasing scratching and grooming responses. However, none of these effects of the CB1 receptor antagonist/inverse agonist was significantly altered by the presence of either dose of sibutramine. In striking contrast to recent reports of acute low-dose interactions (enhanced appetite suppression and reduced side-effects) between rimonabant and naloxone, present results would not appear to support the clinical potential of rimonabant/sibutramine polytherapy for obesity. SN - 1873-5177 UR - https://www.unboundmedicine.com/medline/citation/20026165/Effects_of_acute_low_dose_combined_treatment_with_rimonabant_and_sibutramine_on_appetite_and_weight_gain_in_rats_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-3057(09)00351-7 DB - PRIME DP - Unbound Medicine ER -